个人简历

2016.09-至今 中南大学湘雅药学院|药物化学系 副教授\r
2018.12-2019.12 加拿大皇后大学|化学系/分子科学与生物医药系访问学者\r
2014.10-2016.09 武汉大学|化学与分子科学学院博士后\r
2012.07-2014.09 中国科学院昆明植物研究所助理研究员\r
2007.09-2012.07 中国科学院昆明植物研究所理学博士（药物化学）\r
2003.09-2007.07 中南大学湘雅药学院本科（药学）

研究领域

""基于活性天然产物的新药发现研究，具体包括：\r
1，以活性天然产物为模板，利用新型小分子药物技术发现靶向抗肿瘤药物\r
2，发展新型化学工具，开展活性天然产物的化学生物学研究\r
3，导向复杂活性天然产物骨架高效构建的合成方法学研究\r
4，经典中药方剂的药效物质基础研究""""

近期论文

Xu Deng#, Li-Yang Shi#, Jia-ling Lan#, Yu-Qing Guan, Xiao-yong Zhang, Hui Lv*, Lung-Wa Chung*, Xu-mu Zhang*; Enantioselective rhodium-catalyzed cycloisomerization of 1,6-allenynes to access 5/6-fused bicycle[4.3.0]nonadienes,Nature Communications,2019, 10, 949-959 (#equal contribution, IF = 11.878).\r
\r
Wei Cao, Jin-Bao Fan, Ling-Yang Yan, Guang-Yao Zeng, Jin-Jin Ma, Ya-Jing Wang, Ying-Jun Zhou*,Xu Deng*,Divergent reactivity in CuII-catalyzed oxidative coupling between indole/tryptamine derivatives andβ-arylacrylic acids,Organic Letters,2019, 21, 9556-9662(IF = 6.555).\r
\r
Jin-jin Ma#,Lan Chen#,Jin-bao Fan,Wei Cao,Guang-yao Zeng,Ya-jing Wang,Yuan-jian Li, Ying-jun Zhou*,Xu Deng*, Dual-targeting rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP,European Journal of Medicinal Chemistry,2019,168, 146-153(IF = 4.816).\r
\r
Xiaohui Hua#, Maowen Huang#,Xu Deng#,Jiheng Xu,Yisi Luo,Qipeng Xie,Jiawei Xu,Zhongxian Tian,Jingxia Li,Junlan Zhu,Chao Huang,Qin-shi Zhao*,Haishan Huang*，Chuanshu Huang*,The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein,Cell Death & Differentiation,2019,27, 632-645 (#equal contribution,IF = 8.184).\r
\r
Xiaofeng Chen#,Jinbao Fan#,Guangyao Zeng,Jinjin Ma,Chenxi Wang,Yajing Wang,Yingjun Zhou*,Xu Deng*;Access to 3a-benzoylmethyl pyrrolidino[2,3-b]indolinesviaCuII-catalyzed radical annulation/C3-functionalization sequence,The Journal of Organic Chemistry,2018,83(15), 8322–8330(IF = 4.805).\r
\r
Xu Deng, Yu-Qing Guan, Ning-Ning Huo, Ya-Jing Wang, Hui Lv, Xu-Mu Zhang*, An efficient and modular route to C3*-TunePhos type ligands,Synthesis,2017,49, 3726-3730 (IF = 2.867).\r
\r
Xu Deng, Shao-Fei Ni, Zheng-Yu Han, Yu-Qing Guan, Hui Lv, Li Dang*, Xu-Mu Zhang*, Enantioselective rhodium-catalyzed cycloisomerization of(E)-1,6-enynes.Angewandte Chemie International Edition,2016,55, 6295-6299 (IF = 12.257).\r
\r
Bai-Xin Ye#,Xu Deng#, LiDong Shao, Ying Lu, Run Xiao, YiJie Liu, Yi Jin, YinYin Xie, Mei Dong, Yan Zhao, Ming Gao, Shun Ma, LiuFei Luo, LianRu, Juan He, Yi Chen, Min Deng, TingXi Liu, QinShi Zhao*, SaiJuan Chen*, Zhu Chen*, Vibsanin B preferentially targets HSP90b, inhibit interstitial leukocyte migration and ameliorates experimental autoimmue encephalomyelitis,Journal of Immunology,2015, 194, 4489-4497 (#equal contribution,IF = 4.718).\r
\r
Xu Deng, Kang-Jiang Liang, Xiao-Gang Tong, Ming Ding, Da-Shan Li, Cheng-Feng Xia*, Biomimetic synthesis of chaetominine epimers via copper-catalyzed radical cyclization,Tetrahedron,2015,71, 3699-3704. (IF = 2.379)\r
\r
Xu Deng, Kang-Jiang Liang, Xiao-Gang Tong, Ming Ding, Da-Shan Li, Cheng-Feng Xia*,Copper-catalyzed radical cyclization to access 3-hydroxypyrroloindoline: biomimetic synthesis of protubonine A,Organic Letters,2014, 16, 3276-3279(IF = 6.555).\r
\r
Ling-Mei Kong#,Xu Deng#,Zhi-Li Zuo, Han-Dong Sun, Qin-Shi Zhao*, Yan Li*, Identification and validation of P50 as the cellular target of Eriocalyxin B,Oncotarget,2014, 5, 11354-11364 (#equal contribution).